Isbogrel
Alternative Names: Antexan; CV 4151Latest Information Update: 09 Nov 2000
At a glance
- Originator Takeda
- Class Anti-ischaemics; Antiplatelets; Ischaemic heart disorder therapies; Monounsaturated fatty acids; Pyridines; Small molecules
- Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias; Thrombosis; Transient ischaemic attacks
Most Recent Events
- 09 Nov 2000 Discontinued-preregistration for Transient ischaemic attacks in Japan (Unknown route)
- 08 Nov 2000 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)
- 08 Nov 2000 Investigation in Thrombosis in Japan (PO)